Fig 1: Treatment with arsenic trioxide of SCID mice grafted with MCL cells shows reduced tumor size. (A) Cell death analysis showing the effect of ATO in JeKo-1 cells. JeKo-1 cells were treated with ATO (n=3) and the numbers of cell death were counted. (B) CCK8 assay showing cell viability in JeKo-1 cells treated with or without ATO (n=5). (C) Flow cytometry assay showing changes in cell apoptosis in JeKo-1 cells transfected with WT or DM cyclin D1 expression plasmid and treated with ATO (n=3). Q1: necrotic cells, Q2: apoptotic cells, Q3: pro-apoptotic cells, Q4: live cells. (D) Representative gross anatomy showing tumor size in NCG mice grafted with MCL cells (n=6 in each group). (E and F) Quantification of tumor volume (E) and tumor weight (F) of NCG mice grafted with JeKo-1 cells (n=10 in each group). (G–N) Representative IHC images showing cell number changes and quantification of cyclin D1+ (G and H), Ki67+ (I and J), Bcl2+ (K and L) and B220+ (M and N) cells in tumor tissues from Ctrl mice or ATO-treated mice (Scale bars, 50 μm) (n = 7). (O and P) Flow cytometry images showing numbers and quantification of CD3‒/CD5+/CD19+/CD23‒ cells in blood in NCG mice grafted with MCL cells with or without ATO treatment (n = 3 in each group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Data are represented as mean ± SD. Two-way ANOVA followed by Tukey–Kramer test for multiple comparisons (B and E), two-tailed unpaired Student's t-test analysis (F and P).